New advances in circulating tumor cell‑mediated metastasis of breast cancer (Review)
- Authors:
- Jiang-Shan Zhou
- Zi-Ning Liu
- Yuan-Yuan Chen
- Yu-Xi Liu
- Hua Shen
- Li-Jun Hou
- Yi Ding
-
Affiliations: Laboratory of Pathophysiology, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Laboratory of Pathophysiology, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Department of Mathematics and Statistics, University of Calgary, Alberta T2N 1N4, Canada - Published online on: July 24, 2023 https://doi.org/10.3892/mco.2023.2667
- Article Number: 71
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Park M, Kim D, Ko S, Kim A, Mo K and Yoon H: Breast cancer metastasis: Mechanisms and therapeutic implications. Int J Mol Sci. 23(6806)2022.PubMed/NCBI View Article : Google Scholar | |
|
Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, Jemal A and Siegel RL: Breast cancer statistics, 2022. CA Cancer J Clin. 72:524–541. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Liang Y, Zhang H, Song X and Yang Q: Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 60:14–27. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wang H, Zhang C, Zhang J, Kong L, Zhu H and Yu J: The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: A SEER based study. Oncotarget. 8:26368–26379. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Xiong Z, Deng G, Huang X, Li X, Xie X, Wang J, Shuang Z and Wang X: Bone metastasis pattern in initial metastatic breast cancer: A population-based study. Cancer Manag Res. 10:287–295. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tulotta C and Ottewell P: The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer. 25:R421–R434. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Tahara RK, Brewer TM, Theriault RL and Ueno NT: Bone metastasis of breast cancer. Adv Exp Med Biol. 1152:105–129. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H and Pavlidis N: Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 97:237–244. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Jin L, Han B, Siegel E, Cui Y, Giuliano A and Cui X: Breast cancer lung metastasis: Molecular biology and therapeutic implications. Cancer Biol Ther. 19:858–868. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dan Z, Cao H, He X, Zhang Z, Zou L, Zeng L, Xu Y, Yin Q, Xu M, Zhong D, et al: A pH-Responsive host-guest nanosystem loading succinobucol suppresses lung metastasis of breast cancer. Theranostics. 6:435–445. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Boya M, Chu CH, Liu R, Ozkaya-Ahmadov T and Sarioglu AF: Circulating tumor cell enrichment technologies. Recent Results Cancer Res. 215:25–55. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Di Lorenzo G, Zappavigna S, Crocetto F, Giuliano M, Ribera D, Morra R, Scafuri L, Verde A, Bruzzese D, Iaccarino S, et al: Assessment of total, PTEN(-), and AR-V7(+) circulating tumor cell count by flow cytometry in patients with metastatic castration-resistant prostate cancer receiving enzalutamide. Clin Genitourin Cancer. 19:e286–e298. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ning D, Cui K, Liu M, Ou Y, Wang Z, Zou B, Shen Y, Lu X, Li S and Li P: Comparison of CellSearch and Circulating Tumor Cells (CTC)-Biopsy systems in detecting peripheral blood circulating tumor cells in patients with gastric cancer. Med Sci Monit. 27(e926565)2021.PubMed/NCBI View Article : Google Scholar | |
|
Schuster E, Taftaf R, Reduzzi C, Albert MK, Romero-Calvo I and Liu H: Better together: Circulating tumor cell clustering in metastatic cancer. Trends Cancer. 7:1020–1032. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Andree KC, van Dalum G and Terstappen LW: Challenges in circulating tumor cell detection by the CellSearch system. Mol Oncol. 10:395–407. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Pineiro R: Introduction-Biology of breast cancer metastasis and importance of the analysis of CTCs. Adv Exp Med Biol. 1220:1–10. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Pineiro R, Martinez-Pena I and Lopez-Lopez R: Relevance of CTC clusters in breast cancer metastasis. Adv Exp Med Biol. 1220:93–115. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, et al: Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158:1110–1122. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Alix-Panabieres C and Pantel K: Challenges in circulating tumour cell research. Nat Rev Cancer. 14:623–631. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Yu M, Stott S, Toner M, Maheswaran S and Haber DA: Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol. 192:373–382. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC and Yang JD: Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. Hepatology. 73:422–436. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Chemi F, Mohan S and Brady G: Circulating tumour cells in lung cancer. Recent Results Cancer Res. 215:105–125. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hu M, Wang Z, Wu Z, Ding P, Pei R, Wang Q and Xing C: Circulating tumor cells in colorectal cancer in the era of precision medicine. J Mol Med (Berl). 100:197–213. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, et al: Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 9(016001)2012.PubMed/NCBI View Article : Google Scholar | |
|
Ashworth T: R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 14(146)1869.https://cir.nii.ac.jp/crid/1573105974858034560. | |
|
Nowell PC: The clonal evolution of tumor cell populations. Science. 194:23–28. 1976.PubMed/NCBI View Article : Google Scholar | |
|
Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, Gorin MA, Verdone JE, Pienta KJ, Bader JS and Ewald AJ: Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci USA. 113:E854–E863. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Taftaf R, Kawaguchi M, Chang YF, Chen W, Entenberg D, Zhang Y, Gerratana L, Huang S, Patel DB, et al: Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models. Cancer Discov. 9:96–113. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, Scherrer R, Di Maggio N, Heusermann W, Biehlmaier O, et al: Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 32(108105)2020.PubMed/NCBI View Article : Google Scholar | |
|
Huang L, Ji H, Yin L, Niu X, Wang Y, Liu Y, Xuan Q, Li L, Zhang H, Zhou X, et al: High expression of plakoglobin promotes metastasis in invasive micropapillary carcinoma of the breast via tumor cluster formation. J Cancer. 10:2800–2810. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yin L, Li Q, Mrdenovic S, Chu GC, Wu BJ, Bu H, Duan P, Kim J, You S, Lewis MS, et al: KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway. Breast Cancer Res. 24(7)2022.PubMed/NCBI View Article : Google Scholar | |
|
Xie N, Hu Z, Tian C, Xiao H, Liu L, Yang X, Li J, Wu H, Lu J, Gao J, et al: In vivo detection of CTC and CTC plakoglobin status helps predict prognosis in patients with metastatic breast cancer. Pathol Oncol Res. 26:2435–2442. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Hassn Mesrati M, Syafruddin SE, Mohtar MA and Syahir A: CD44: A multifunctional mediator of cancer progression. Biomolecules. 11(1850)2021.PubMed/NCBI View Article : Google Scholar | |
|
Hiraga T and Nakamura H: Comparable roles of CD44v8-10 and CD44s in the development of bone metastases in a mouse model. Oncol Lett. 12:2962–2969. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Kolev VN, Tam WF, Wright QG, McDermott SP, Vidal CM, Shapiro IM, Xu Q, Wicha MS, Pachter JA and Weaver DT: Inhibition of FAK kinase activity preferentially targets cancer stem cells. Oncotarget. 8:51733–51747. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Lev S: Targeted therapy and drug resistance in triple-negative breast cancer: The EGFR axis. Biochem Soc Trans. 48:657–665. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Adorno-Cruz V, Chang YF, Jia Y, Kawaguchi M, Dashzeveg NK, Taftaf R, Ramos EK, Schuster EJ, El-Shennawy L, et al: EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics. 11:6632–6643. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, et al: MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 4(1393)2013.PubMed/NCBI View Article : Google Scholar | |
|
Taftaf R, Liu X, Singh S, Jia Y, Dashzeveg NK, Hoffmann AD, El-Shennawy L, Ramos EK, Adorno-Cruz V, Schuster EJ, et al: ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun. 12(4867)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bui TM, Wiesolek HL and Sumagin R: ICAM-1: A master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis. J Leukoc Biol. 108:787–799. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wei RR, Sun DN, Yang H, Yan J, Zhang X, Zheng XL, Fu XH, Geng MY, Huang X and Ding J: CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacol Sin. 39:1326–1337. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Niu Y, Bao L, Chen Y, Wang C, Luo M, Zhang B, Zhou M, Wang JE, Fang YV, Kumar A, et al: HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated angiogenesis and breast cancer metastasis. Cancer Res. 80:964–975. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chang PH, Chen MC, Tsai YP, Tan GYT, Hsu PH, Jeng YM, Tsai YF, Yang MH and Hwang-Verslues WW: Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proc Natl Acad Sci USA. 118(e2014408118)2021.PubMed/NCBI View Article : Google Scholar | |
|
Tashireva LA, Savelieva OE, Grigoryeva ES, Nikitin YV, Denisov EV, Vtorushin SV, Zavyalova MV, Cherdyntseva NV and Perelmuter VM: Heterogeneous manifestations of epithelial-mesenchymal plasticity of circulating tumor cells in breast cancer patients. Int J Mol Sci. 22(2504)2021.PubMed/NCBI View Article : Google Scholar | |
|
Fabisiewicz A and Grzybowska E: CTC clusters in cancer progression and metastasis. Med Oncol. 34(12)2017.PubMed/NCBI View Article : Google Scholar | |
|
Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, Krol I, Scheidmann MC, Beisel C, Stirnimann CU, et al: Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 176:98–112.e14. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Sheaffer KL, Elliott EN and Kaestner KH: DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. Cancer Prev Res (Phila). 9:534–546. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Zmetakova I, Kalinkova L, Smolkova B, Horvathova Kajabova V, Cierna Z, Danihel L, Bohac M, Sedlackova T, Minarik G, Karaba M, et al: A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients. Cancer Sci. 110:1695–1704. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Hapach LA, Carey SP, Schwager SC, Taufalele PV, Wang W, Mosier JA, Ortiz-Otero N, McArdle TJ, Goldblatt ZE, Lampi MC, et al: Phenotypic heterogeneity and metastasis of breast cancer cells. Cancer Res. 81:3649–3663. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Han HJ, Sung JY, Kim SH, Yun UJ, Kim H, Jang EJ, Yoo HE, Hong EK, Goh SH, Moon A, et al: Fibronectin regulates anoikis resistance via cell aggregate formation. Cancer Lett. 508:59–72. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Mutlu BR, Dubash T, Dietsche C, Mishra A, Ozbey A, Keim K, Edd JF, Haber DA, Maheswaran S and Toner M: In-flow measurement of cell-cell adhesion using oscillatory inertial microfluidics. Lab Chip. 20:1612–1620. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Neophytou CM, Trougakos IP, Erin N and Papageorgis P: Apoptosis deregulation and the development of cancer multi-drug resistance. Cancers (Basel). 13(4363)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kim H, Sung JY, Park EK, Kho S, Koo KH, Park SY, Goh SH, Jeon YK, Oh S, Park BK, et al: Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor. Br J Cancer. 116:370–381. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Thangavel H, De Angelis C, Vasaikar S, Bhat R, Jolly MK, Nagi C, Creighton CJ, Chen F, Dobrolecki LE, George JT, et al: A CTC-cluster-specific signature derived from OMICS analysis of patient-derived xenograft tumors predicts outcomes in basal-like breast cancer. J Clin Med. 8(1772)2019.PubMed/NCBI View Article : Google Scholar | |
|
Yu M: Metastasis stemming from circulating tumor cell clusters. Trends Cell Biol. 29:275–276. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Babaei G, Aziz SG and Jaghi NZZ: EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomed Pharmacother. 133(110909)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kapeleris J, Zou H, Qi Y, Gu Y, Li J, Schoning J, Monteiro MJ and Gu W: Cancer stemness contributes to cluster formation of colon cancer cells and high metastatic potentials. Clin Exp Pharmacol Physiol. 47:838–847. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Martinez-Pena I, Hurtado P, Carmona-Ule N, Abuin C, Davila-Ibanez AB, Sanchez L, Abal M, Chaachou A, Hernández-Losa J, Cajal SRY, et al: Dissecting breast cancer circulating tumor cells competence via modelling metastasis in zebrafish. Int J Mol Sci. 22(9279)2022.PubMed/NCBI View Article : Google Scholar | |
|
Kawaguchi M, Dashzeveg N, Cao Y, Jia Y, Liu X, Shen Y and Liu H: Extracellular Domains I and II of cell-surface glycoprotein CD44 mediate its trans-homophilic dimerization and tumor cluster aggregation. J Biol Chem. 295:2640–2649. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Manupati K, Yeeravalli R, Kaushik K, Singh D, Mehra B, Gangane N, Gupta A, Goswami K and Das A: Activation of CD44-Lipoprotein lipase axis in breast cancer stem cells promotes tumorigenesis. Biochim Biophys Acta Mol Basis Dis. 1867(166228)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang X, Sun Q, Liu Q, Wang C, Yao R and Wang Y: CTC immune escape mediated by PD-L1. Med Hypotheses. 93:138–139. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Liu Q, Liao Q and Zhao Y: Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. Med Hypotheses. 87:34–39. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lo HC, Xu Z, Kim IS, Pingel B, Aguirre S, Kodali S, Liu J, Zhang W, Muscarella AM, Hein SM, et al: Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis. Nat Cancer. 1:709–722. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, et al: Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 566:553–557. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Luo L and He Y: Magnetically driven microfluidics for isolation of circulating tumor cells. Cancer Med. 9:4207–4231. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Sierra-Agudelo J, Rodriguez-Trujillo R and Samitier J: Microfluidics for the isolation and detection of circulating tumor cells. Adv Exp Med Biol. 1379:389–412. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Khetani S, Mohammadi M and Nezhad AS: Filter-based isolation, enrichment, and characterization of circulating tumor cells. Biotechnol Bioeng. 115:2504–2529. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Riethdorf S, O'Flaherty L, Hille C and Pantel K: Clinical applications of the CellSearch platform in cancer patients. Adv Drug Deliv Rev. 125:102–121. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ramos-Medina R, Lopez-Tarruella S, Del Monte-Millan M, Massarrah T and Martin M: Technical challenges for CTC implementation in breast cancer. Cancers (Basel). 13(4619)2021.PubMed/NCBI View Article : Google Scholar | |
|
Deng Z, Wu S, Wang Y and Shi D: Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 83(104237)2022.PubMed/NCBI View Article : Google Scholar | |
|
Menyailo ME, Bokova UA, Ivanyuk EE, Khozyainova AA and Denisov EV: Metastasis prevention: Focus on metastatic circulating tumor cells. Mol Diagn Ther. 25:549–562. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Krol I, Schwab FD, Carbone R, Ritter M, Picocci S, De Marni ML, Stepien G, Franchi GM, Zanardi A, Rissoglio MD, et al: Detection of clustered circulating tumour cells in early breast cancer. Br J Cancer. 125:23–27. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Deutsch TM, Riethdorf S, Fremd C, Feisst M, Nees J, Fischer C, Hartkopf AD, Pantel K, Trumpp A, Schütz F, et al: HER2-targeted therapy influences CTC status in metastatic breast cancer. Breast Cancer Res Treat. 182:127–136. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Goodman CR, Seagle BL, Friedl TWP, Rack B, Lato K, Fink V, Cristofanilli M, Donnelly ED, Janni W, Shahabi S and Strauss JB: Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 4(e180163)2018.PubMed/NCBI View Article : Google Scholar | |
|
Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, et al: Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol. 26:510–516. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, Bachelot T, Bourgeois H, Gonçalves A, Ladoire S, et al: Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-Negative metastatic breast cancer: The STIC CTC randomized clinical trial. JAMA Oncol. 7:34–41. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, et al: Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: Preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 6:1410–1415. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y, Lv Y, Niu Y, Su H and Feng A: Role of circulating tumor cell (CTC) monitoring in evaluating prognosis of triple-negative breast cancer patients in China. Med Sci Monit. 23:3071–3079. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K and Alix-Panabières C: Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem. 60:214–221. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, et al: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol. 15:406–414. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Guan X, Ma F, Li C, Wu S, Hu S, Huang J, Sun X, Wang J, Luo Y, Cai R, et al: The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Cancer Commun (Lond). 39(1)2019.PubMed/NCBI View Article : Google Scholar | |
|
Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K and Rydén L: Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 20(48)2018.PubMed/NCBI View Article : Google Scholar | |
|
Pang S, Li H, Xu S, Feng L, Ma X, Chu Y, Zou B, Wang S and Zhou G: Circulating tumour cells at baseline and late phase of treatment provide prognostic value in breast cancer. Sci Rep. 11(13441)2021.PubMed/NCBI View Article : Google Scholar | |
|
Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, et al: Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. Ann Oncol. 28:103–109. 2017.PubMed/NCBI View Article : Google Scholar |
